CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Financial Flexibility Index
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Financial Flexibility Index of -1.55x as of December 2025. Free cash flow of $-1.75 Million (operating CF $-2.05 Million minus capex $297.96K) represents -2% of total liabilities ($1.13 Million). Check strategic asset allocation of CytoMed Therapeutics Limited Ordinary Sh to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
CytoMed Therapeutics Limited Ordinary Shares Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for CytoMed Therapeutics Limited Ordinary Shares across 7 annual periods. See GDTC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Year-by-year free cash flow to debt coverage for CytoMed Therapeutics Limited Ordinary Shares. For the full company profile including market capitalisation, see CytoMed Therapeutics Limited Ordinary Sh market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.65x | $-2.99 Million | $-3.70 Million | $1.13 Million | ▼ -106.9% |
| 2024 | -1.28x | $-1.31 Million | $-2.71 Million | $1.02 Million | ▲ +58.6% |
| 2023 | -3.09x | $-3.48 Million | $-3.54 Million | $1.13 Million | ▼ -1449.8% |
| 2022 | -0.20x | $-928.92K | $-1.40 Million | $4.66 Million | ▲ +38.5% |
| 2021 | -0.32x | $-1.13 Million | $-1.72 Million | $3.50 Million | ▼ -61.5% |
| 2020 | -0.20x | $-671.13K | $-916.39K | $3.35 Million | ▼ -137.1% |
| 2019 | 0.54x | $544.52K | $-640.52K | $1.01 Million | — |